The role of enzalutamide in the treatment of prostate cancer from the perspective of Polish oncologists

For several years, prostate cancer has remained the most common malignancy in male patients Poland. A large number of combined with rising costs therapy translate into a significant socio-economic burden. In clinical oncologist’s practice, we usually deal advanced cancer. Taking account poorer prognosis disease, development new therapeutic options as well their adequate selection is paramount importance. Enzalutamide one second-generation androgen axis inhibitors, which ability to overcome resistance deprivation by inhibiting androgen-DNA signalling on levels. Its efficacy and safety had been proven numerous phase II III studies it registered regulatory authorities United States European Union treatment mCRPC, mCSPC nmCRPC. this article selected issues related are discussed, particular emphasis role enzalutamide (including its mechanism action, indications, safety).